Regional variant of Guillain-Barré syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:231416
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Regional variants of Guillain-Barré syndrome (GBS) are a group of acute immune-mediated neuropathies that affect specific, limited regions of the peripheral nervous system rather than causing the widespread ascending paralysis seen in classic GBS. These variants are considered incomplete or localized forms of the broader Guillain-Barré spectrum. They typically develop days to weeks after an infectious illness, most commonly a respiratory or gastrointestinal infection, and are thought to result from molecular mimicry in which antibodies generated against infectious agents cross-react with components of peripheral nerves. Regional variants include conditions such as pharyngeal-cervical-brachial (PCB) weakness, facial diplegia with paresthesias, and other localized presentations that do not meet criteria for the more well-known Miller Fisher syndrome or classic acute inflammatory demyelinating polyneuropathy (AIDP). In pharyngeal-cervical-brachial variant, patients experience weakness predominantly in the oropharyngeal, neck, and upper limb muscles, which can lead to difficulty swallowing, neck weakness, and arm weakness while the legs are relatively spared. Facial diplegia with paresthesias presents with bilateral facial weakness and sensory symptoms in the limbs. Anti-ganglioside antibodies, such as anti-GT1a or anti-GQ1b, may be detected in some patients, supporting the autoimmune etiology. Diagnosis is based on clinical presentation, nerve conduction studies, cerebrospinal fluid analysis (which may show albuminocytologic dissociation), and serological testing for anti-ganglioside antibodies. Treatment follows the same principles as classic GBS and includes intravenous immunoglobulin (IVIg) or plasma exchange (plasmapheresis), along with supportive care including monitoring for respiratory compromise. Most patients have a favorable prognosis with gradual recovery over weeks to months, though some may experience residual deficits. Early recognition is important to distinguish these variants from other neurological emergencies such as brainstem stroke or myasthenia gravis.

Also known as:

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Regional variant of Guillain-Barré syndrome.

View clinical trials →

No actively recruiting trials found for Regional variant of Guillain-Barré syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Regional variant of Guillain-Barré syndrome community →

No specialists are currently listed for Regional variant of Guillain-Barré syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Regional variant of Guillain-Barré syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Regional variant of Guillain-Barré syndromeForum →

No community posts yet. Be the first to share your experience with Regional variant of Guillain-Barré syndrome.

Start the conversation →

Latest news about Regional variant of Guillain-Barré syndrome

No recent news articles for Regional variant of Guillain-Barré syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Regional variant of Guillain-Barré syndrome

What is Regional variant of Guillain-Barré syndrome?

Regional variants of Guillain-Barré syndrome (GBS) are a group of acute immune-mediated neuropathies that affect specific, limited regions of the peripheral nervous system rather than causing the widespread ascending paralysis seen in classic GBS. These variants are considered incomplete or localized forms of the broader Guillain-Barré spectrum. They typically develop days to weeks after an infectious illness, most commonly a respiratory or gastrointestinal infection, and are thought to result from molecular mimicry in which antibodies generated against infectious agents cross-react with compo

How is Regional variant of Guillain-Barré syndrome inherited?

Regional variant of Guillain-Barré syndrome follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.